Analysts See $-0.26 EPS for Trevena, Inc. (TRVN)

February 15, 2018 - By Maria Brooks

 Analysts See $ 0.26 EPS for Trevena, Inc. (TRVN)

Analysts expect Trevena, Inc. (NASDAQ:TRVN) to report $-0.26 EPS on March, 14.They anticipate $0.41 EPS change or 61.19 % from last quarter’s $-0.67 EPS. After having $-0.27 EPS previously, Trevena, Inc.’s analysts see -3.70 % EPS growth. It closed at $1.7 lastly. It is down 52.53% since February 15, 2017 and is downtrending. It has underperformed by 69.23% the S&P500.

Trevena, Inc. (NASDAQ:TRVN) Ratings Coverage

Among 14 analysts covering Trevena Inc (NASDAQ:TRVN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Trevena Inc had 23 analyst reports since August 3, 2015 according to SRatingsIntel. Oppenheimer maintained Trevena, Inc. (NASDAQ:TRVN) rating on Friday, July 21. Oppenheimer has “Buy” rating and $800 target. FBR Capital maintained it with “Outperform” rating and $8 target in Wednesday, February 22 report. JMP Securities maintained the stock with “Buy” rating in Wednesday, September 2 report. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, February 23. The firm has “Buy” rating by Brean Capital given on Monday, August 3. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. As per Thursday, February 2, the company rating was initiated by Ladenburg Thalmann. On Monday, June 19 the stock rating was maintained by Aegis Capital with “Buy”. Cowen & Co maintained Trevena, Inc. (NASDAQ:TRVN) on Thursday, August 3 with “Buy” rating. The rating was initiated by Oppenheimer on Thursday, January 5 with “Outperform”.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has market cap of $105.91 million. The Company’s product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. It currently has negative earnings.

Another recent and important Trevena, Inc. (NASDAQ:TRVN) news was published by which published an article titled: “Trevena Promotes Carrie Bourdow to Executive Vice President and Chief …” on February 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.